CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenues:
Total revenues	$ 7,082	$ 6,954	$ 13,749	$ 13,640
Costs and expenses:
Cost of goods sold	1,501	1,544	3,041	3,096
Research and development expenses	1,491	1,351	2,870	2,871
Acquired in-process research and development expenses	61	38	315	4,169
In-process research and development impairments	190	0	190	2,430
Selling, general and administrative expenses	1,365	1,377	2,623	2,752
Total costs and expenses	4,608	4,309	9,038	15,317
Operating income (loss)	2,474	2,644	4,711	(1,678)
Interest expense	254	237	513	491
Other (income) expense, net	(208)	355	120	265
Income (loss) before income taxes	2,429	2,053	4,077	(2,433)
Income tax expense	468	438	802	123
Net income (loss)	1,960	1,614	3,275	(2,556)
Net income attributable to noncontrolling interest	0	0	0	0
Net income (loss) attributable to Gilead	$ 1,960	$ 1,614	$ 3,275	$ (2,556)
Basic earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1.57	$ 1.29	$ 2.63	$ (2.05)
Diluted earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1.56	$ 1.29	$ 2.61	$ (2.05)
Shares used in basic earnings (loss) per share attributable to Gilead calculation (in shares)	1,245	1,247	1,246	1,247
Shares used in diluted earnings (loss) per share attributable to Gilead calculation (in shares)	1,255	1,251	1,257	1,247
Product sales
Revenues:
Total revenues	$ 7,054	$ 6,912	$ 13,668	$ 13,559
Royalty, contract and other revenues
Revenues:
Total revenues	$ 27	$ 41	$ 81	$ 81